Postoperative pain of VATS
Conditions
Interventions
Tegileridine Gruop:Slowly pump 0.75mg of Tegileridine injection and 0.05mg of PICIA each time within 10 minutes, with a locking time of 10 minutes.
Sufentanil Group:Slowly pump 3 µg of sufentanil injection and PICA1 µg each time within 10 minutes, with a locking time of 10 minutes.
Sponsors
Renmin Hospital of Wuhan University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Scheduled for elective VATS lobectomy or segmentectomy under general anesthesia with endotracheal intubation, with an estimated surgical duration of 1-3 hours; 2. Aged >=18 years, regardless of gender; 3. Body Mass Index (BMI) between 18 and 30 kg/m²; 4. American Society of Anesthesiologists (ASA) physical status classification of I or II; 5. Voluntarily sign the informed consent form before any trial-related activities begin, fully understand the purpose and significance of this trial, and voluntarily comply with the trial procedures;
Exclusion criteria
Exclusion criteria: 1. Patients with a history of obstructive sleep apnea syndrome, severe respiratory depression such as oxygen saturation < 90%, or a history of acute or severe bronchial asthma; 2. Patients with a history of severe cardiovascular or cerebrovascular diseases (such as myocardial infarction or unstable angina, or severe arrhythmias like grade II or higher atrioventricular block, or ischemic stroke of NYHA class II or above); 3. Patients with known or suspected gastrointestinal obstruction, including those with paralytic ileus; 4. Patients allergic to opioids or any component of the investigational drug; 5. Subjects with a history of mental illness (such as schizophrenia, depression, etc.) and cognitive dysfunction; 6. Patients with advanced malignant tumors or malignant tumor patients with extensive metastasis; 7. Subjects suffering from other somatic pain that may affect postoperative pain assessment; 8. Subjects with a history of drug, medication, and/or alcohol abuse within 1 year prior to randomization; 9. Female subjects who are pregnant or breastfeeding; 10. Subjects whom the investigator deems unsuitable for participation in the trial due to any other factors.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| AUC-NRS48; | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse Drug Reaction (ADR) Evaluation;Analgesia satisfaction;Incidence of postoperative nausea and vomiting (PONV);Incidence of respiratory depression; | — |
Countries
China
Contacts
Public ContactZhongyuan Xia
Renmin Hospital of Wuhan University
Outcome results
None listed